What if you could target the root cause of cell therapy's limited success in solid tumors—the diverse immunosuppressive mechanisms within the tumor microenvironment (TME)?

What if you could address the fundamental barriers to cell therapy effectiveness in solid tumors, rather than merely mitigating secondary functional impairments?

🚀 Big news! KiraGen Bio is a Boston Regional Finalist in the Harvard Business School New Venture Competition – Alumni Track! This is a huge milestone for our AI-driven CAR-T therapies tackling solid tumors like GBM. Next stop: Global Finals for a chance at $75K! Onwards and Upwards! 🏆

Our CEO Aaron Edwards joined Jon Chee on @Excedr’s Biotech Startups Podcast 🎙️ In Part 1 of 4, he shares how early wonder, queerness, & a few real-life “Ms. Frizzles” helped shape his path—and KiraGen’s mission to conquer the TME.

We are honored to be part of the inaugural AI BioHub from C10 Labs & LabCentral—bringing AI and biology together to accelerate the future of drug development.

Our TME-Guards are like noise-cancelling headphones for CAR-T cells — silencing the suppressive signals of the tumor microenvironment so they can do their job.

Meet the newest member of Team KiraGen Bio — our CAR-T cell mascot 🎧 Outfitted with AI-powered, noise-canceling headphones (our multiplex gene edits), it’s built to block out the solid tumor suppressive “noise” & keep fighting on! Designed to cure. Built to endure.

Our new website is live 🚀 KiraGen Bio is advancing multiplex-edited, off-the-shelf cell therapies designed to block tumor suppression signals and bring durable treatments to solid tumors. Explore more → kiragenbio.com